SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop
Our findings not only underscore the promise of SEC14L3 as a therapeutic target but also unveil an SEC14L3/RPS3/NFκB positive feedback loop that curtails ccRCC progression. Modulating SEC14L3 expression to engage this positive feedback loop might herald novel avenues for ccRCC treatment.
Authors
- Guangchun Wang (ORCID: https://orcid.org/0000-0002-0873-9163)
- Jinliang Ni (ORCID: https://orcid.org/0000-0003-4751-2057)
- Guangcan Yang (ORCID: https://orcid.org/0000-0002-2767-2718)
- Houliang Zhang (ORCID: https://orcid.org/0000-0002-9283-1295)
- Bo Peng (ORCID: https://orcid.org/0000-0001-5286-7413)
- Ziming Jiang (ORCID: https://orcid.org/0000-0003-4762-7516)
- Yifan Zhang (ORCID: https://orcid.org/0009-0001-2662-1126)
- Haipeng Zhang (ORCID: https://orcid.org/0000-0001-9188-542X)
- Ming Luo (ORCID: https://orcid.org/0000-0002-5651-003X)
- Jiayi Wan
- Keyi Wang
- Wei Song (ORCID: https://orcid.org/0000-0001-9814-419X)
Institutions
- Tongji University (CN)
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanghai Tenth People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1186/s13046-024-03206-5
- Citations
- 10
- Primary Topic
- Renal and related cancers
- Type
- article
- Field-Weighted Citation Impact
- 2.34
Funders
- National Natural Science Foundation of China
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission